RxDoctor Payments Data

Jung Gorton, MD

Internal Medicine · Pensacola, FLNPI 1134179716

Payments from drug & device makers

$788in general payments, 2019–2025

Across 55 payments — averaging $14.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$202
  • AstraZeneca$144
  • Amgen$66
  • GSK$58
  • Lilly USA, LLC$49
  • Merck$37
  • plus $232 from 11 others

What the payments were for

  • Food & beverage$74394%
  • Education$456%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$788 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$168,457
Medicare patients
571
Services billed
1,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide174$224,300
OzempicSemaglutide135$193,144
JardianceEmpagliflozin73$81,834
EliquisApixaban65$62,500
TrulicityDulaglutide42$60,628
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$32,413
JanuviaSitagliptin Phosphate27$30,954
LinzessLinaclotide24$28,673
MyrbetriqMirabegron23$27,587
Janumet XrSitagliptin Phos/Metformin Hcl12$11,043
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$10,685
XareltoRivaroxaban11$9,360
Breo ElliptaFluticasone/Vilanterol21$9,336
Humalog Kwikpen U-100Insulin Lispro41$8,203
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$6,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$49$284,928216 claims
Novo NordiskOzempic$202$193,144135 claims
PfizerEliquis$12$62,50065 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$58$52,43572 claims
MerckJanuvia, Janumet Xr$37$41,99739 claims
Astellas Pharma US IncMyrbetriq$26$27,58723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →